Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company and a subsidiary of Fortress Biotech, Inc. The company is dedicated to developing and commercializing innovative cancer immunotherapy products that harness the patient's own immune system to target and eradicate cancer cells. Mustang Bio’s approach involves acquiring the rights to cutting-edge technologies through licensing or ownership, funding their research and development, and then either out-licensing or bringing these technologies to market.
Mustang Bio has established strategic partnerships with notable institutions, including the City of Hope National Medical Center (COH) and the Fred Hutchinson Cancer Research Center. These collaborations focus on developing advanced Chimeric Antigen Receptor (CAR) engineered T cell (CAR T) therapies for various cancers.
Among Mustang’s core projects, their key programs are in Phase 1 clinical trials at COH. The MB-101 program is aimed at treating brain cancer, while MB-102 is being developed as a therapeutic agent for acute myeloid leukemia. Additionally, Mustang Bio is concentrating on gene therapies for rare genetic disorders, CAR T therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Recently, Mustang Bio has reported positive interim data from their multicenter Phase 1/2 clinical trial, showcasing a favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients. For more detailed insights, visit the 65th ASH Annual Meeting and Exposition website.
For further information and ongoing updates about Mustang Bio, you can reach them through the following contacts:
- Jaclyn Jaffe and Nicole McCloskey - Mustang Bio, Inc., (781) 652-4500, ir@mustangbio.com
- Tony Plohoros - Media Relations Contact, 6 Degrees, (908) 591-2839, tplohoros@6degreespr.com
Mustang Bio, Inc. (Nasdaq: MBIO) announced a 15-for-1 reverse stock split effective April 4, 2023, to comply with Nasdaq’s $1.00 minimum bid price requirement. This approval came from the Board of Directors and stockholders representing approximately 62.2% of voting power. The outstanding shares will decrease from approximately 109.4 million to about 7.3 million. Stockholders will not receive fractional shares but will instead receive a cash payment. Mustang continues to focus on cell and gene therapies targeting hematologic cancers and genetic diseases.
FAQ
What is the current stock price of Mustang Bio (MBIO)?
What is the market cap of Mustang Bio (MBIO)?
What is Mustang Bio, Inc.?
What are Mustang Bio's core areas of focus?
Who are Mustang Bio's key partners?
What are Mustang Bio's lead programs?
What recent achievements has Mustang Bio reported?
How does Mustang Bio acquire its technologies?
What is CAR T therapy?
How can I contact Mustang Bio for more information?
Where can I find more detailed updates on Mustang Bio's clinical trials?
Who should media inquiries be directed to?
